Arkema (ENXTPA:AKE) Could Be 10% Undervalued On Shanghai R And D Expansion

Arkema (ENXTPA:AKE) has just opened an expanded Shanghai R&D Center, a sizeable step in its Asia-focused research network that could influence how investors view the group’s specialty materials exposure.

The Shanghai expansion comes after a busy period for Arkema, with a new low carbon acrylic acid unit in Carling and fresh visibility at SEMICON West 2026. The shares now trade at €56.4 with a 1 year total shareholder return of 16.7%, while the 3 year total shareholder return has declined 23.2%, indicating that recent momentum has picked up from a weaker longer term stretch.

Scan Arkema’s peers that are tapping industrial decarbonization and advanced materials demand by reviewing the hand-picked 194 high quality undervalued stocks now.

With Arkema reshaping its R&D footprint and the share price back at €56.4 after a tougher three year stretch, does it make more sense to commit capital now, or to wait for a cheaper entry as the valuation story unfolds?

Most Popular Narrative: 10% Undervalued

Arkema’s most followed valuation view points to a fair value of €62.64 against the current €56.4, which puts the refreshed Shanghai R&D push and broader specialty tilt under a lens of underappreciated cash generation.

The main factor is that Arkema sustains disciplined cost savings and capex control while its Asia led growth and ramping projects in PA11, PVDF and fluorogases continue to support margins and cash generation through a weak cycle in Europe and North America.

The current valuation implies the market is not fully pricing in Arkema’s delivery on early cost savings, the incremental EBITDA from recent capacity ramps and the focus on higher margin Specialty Materials. This combination underpins the view that the stock is undervalued and the overall narrative is positive.

See why 32 investors see Arkema as 10% undervalued.

Result: Fair Value of €62.64 (UNDERVALUED)

Still, Arkema’s story could be knocked off course if weakness in European construction drags on, or if acrylics pricing cycles turn against the intermediates unit again.

Find out about the key risks to this Arkema narrative.

Next Steps

Views on Arkema’s balance of risks and rewards are clearly split, so act while sentiment is still forming and weigh the 2 key rewards and 3 important warning signs.

Looking for more ideas beyond Arkema?

If Arkema has your attention, do not stop here. The best opportunities often sit one layer deeper in the market than the headlines you already know.

• Target reliable income and stress test your passive cash flow plans by reviewing the 218 dividend fortresses before yields move on you.
• Hunt for quality at a discount and pressure test Arkema against peers by scanning the 615 high quality undiscovered gems while they still fly under the radar.
• Dial down portfolio volatility and shore up capital with the 227 resilient stocks with low risk scores so you are not reacting after the market has already moved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com